MX2014013913A - Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21. - Google Patents

Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21.

Info

Publication number
MX2014013913A
MX2014013913A MX2014013913A MX2014013913A MX2014013913A MX 2014013913 A MX2014013913 A MX 2014013913A MX 2014013913 A MX2014013913 A MX 2014013913A MX 2014013913 A MX2014013913 A MX 2014013913A MX 2014013913 A MX2014013913 A MX 2014013913A
Authority
MX
Mexico
Prior art keywords
proteins
growth factor
fibroblast growth
therapeutic uses
therapeutic
Prior art date
Application number
MX2014013913A
Other languages
English (en)
Spanish (es)
Inventor
Yanfei Linda Ma
Armando Rafael Irizarry Rovira
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014013913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2014013913A publication Critical patent/MX2014013913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2014013913A 2012-05-15 2013-05-09 Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21. MX2014013913A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15
PCT/US2013/040275 WO2013173158A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Publications (1)

Publication Number Publication Date
MX2014013913A true MX2014013913A (es) 2015-02-17

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013913A MX2014013913A (es) 2012-05-15 2013-05-09 Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21.

Country Status (21)

Country Link
US (1) US20150141335A1 (OSRAM)
EP (1) EP2852398A1 (OSRAM)
JP (1) JP2015522539A (OSRAM)
KR (1) KR20150002801A (OSRAM)
CN (1) CN104302311A (OSRAM)
AU (1) AU2013263188A1 (OSRAM)
BR (1) BR112014028413A2 (OSRAM)
CA (1) CA2869320A1 (OSRAM)
CL (1) CL2014002846A1 (OSRAM)
CO (1) CO7131381A2 (OSRAM)
EA (1) EA201491856A1 (OSRAM)
HK (1) HK1202800A1 (OSRAM)
IL (1) IL235482A0 (OSRAM)
MA (1) MA37506B1 (OSRAM)
MX (1) MX2014013913A (OSRAM)
PE (1) PE20142432A1 (OSRAM)
PH (1) PH12014502537A1 (OSRAM)
SG (1) SG11201407655TA (OSRAM)
TN (1) TN2014000409A1 (OSRAM)
WO (1) WO2013173158A1 (OSRAM)
ZA (1) ZA201407532B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016039339A1 (ja) * 2014-09-08 2016-03-17 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
EP3935075A4 (en) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
KR20240034235A (ko) 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
CA2869320A1 (en) 2013-11-21
ZA201407532B (en) 2016-05-25
JP2015522539A (ja) 2015-08-06
US20150141335A1 (en) 2015-05-21
CL2014002846A1 (es) 2015-01-30
PE20142432A1 (es) 2015-01-22
TN2014000409A1 (en) 2015-12-21
PH12014502537A1 (en) 2015-01-21
SG11201407655TA (en) 2014-12-30
EA201491856A1 (ru) 2015-03-31
AU2013263188A1 (en) 2014-10-16
MA37506B1 (fr) 2017-03-31
CN104302311A (zh) 2015-01-21
MA37506A1 (fr) 2016-01-29
KR20150002801A (ko) 2015-01-07
WO2013173158A1 (en) 2013-11-21
BR112014028413A2 (pt) 2017-11-07
CO7131381A2 (es) 2014-12-01
HK1202800A1 (en) 2015-10-09
IL235482A0 (en) 2014-12-31
EP2852398A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
PH12014501702A1 (en) Imidazopyrrolidinone compounds
CU24115B1 (es) Péptidos derivados del factor de crecimiento de fibroblastos 21 ( fgf21) útiles como reguladores metabólicos
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
MY158992A (en) Forms of rifaximin and uses thereof
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
IN2014DN11201A (OSRAM)
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX337206B (es) Variantes de factor neurotrófico derivado de celulas gliales humanas.
MX338113B (es) Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
TW201129374A (en) Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos